hepatitis tx Flashcards
Peginterferon alfa
HBV agent/HCV agent
MOA: inhibits viral penetration, tln, txn, protein processing, maturation and release
- must be given subq: but has slower clearance, 1x/week injections
ADR’s: experience flu-like illness w/in first week
- increase in hepatic enzymes
- neurotoxicity, meylosupression, fatigue
CI’s: hepatic decomposition, psychiatric disease
Adefovir
HBV agent
Nucleoside/NT analogs (NA’s): interfere w/ viral replication- inhibit HBV DNA pol, chain termination after incorporation into viral DNA
ADR’s: h/a, diarrhea, ab. pain; nephrotoxicity
Entecavir
HBV agent
Nucleoside/NT analogs (NA’s): interfere w/ viral replication-
MOA: inhibits DNA polymerase
ADR’s: welll- tolerated
** first line therapy for HBV
Lamivudine
(3TC) HBV agent
Nucleoside/NT analogs (NA’s): interfere w/ viral replication-
MOA: inhibits DNA pol
ADR’s: excellent safety profile, including use during pregnancy
USE: has high amount of resistnace, not first line therapy
Telbivudine
HBV agent
Nucleoside/NT analogs (NA’s): interfere w/ viral replication
MOA- inhibits DNA pol via competitive inhibition, causing chain termination
CIS’s: concurrent use w/ interferon alfa can cause peripheral neuropathy
not recommended first line
Tenofovir
HBV agent
Nucleoside/NT analogs (NA’s): interfere w/ viral replication-
MOA: comp. inhibits DNA pol, causing chain termination
ADR’s: nausea, diarrhea, vomiting, decreased bone mineral density
Use: recommended first-line therapy for HBV
resistance is rare
Ribavarin
HCV agent
MOA: inhibits initiation/elongation of RNA –> inhibition of viral protein synth (inhibits RNA pol)
ADR’s: dose dependent hemolytic anemia , teratogenic, oncogenic
Used for Chronic HCV
CI’s: anemia, ESRF, ischemic vascular disease, pregnancy
simeprevir
(OLYSIO) HCV agent
MOA: direct acting antiviral
ADR’s: skin rash/puritis
DDI’s: avoid with CYP inducers (rifampin) – super expensive tx
Sofosbuvir
(Sovaldi) HCV agent
MOA: direct acting antiviral - inhibits RNA pol
ADR’s: fatigue, h/a, insomnia
expensive!!!
Boceprevir
(Incivek) HCV agent = protease inhibitor
no longer recommended
Telaprevir
(Victrelis) HCV agent = protease inhibitor
no longer recommended
+ HBsAG
HBV surface protein; high level occur during acute/chronic infection - means pt. is infectious
+ anti-HBs
interpreted as recovery or immunity from HBV - also arise after succesful vaccination
+ anti-HBc
total hepatitis B core Ab - appears at onset of infection (will persist for life) and indicates previous or ongoing infection
IgM anti-HBc
delineates recent infection with HBV w/in 6 mos